Design of the STRIVE-IPF trial- study of therapeutic plasma exchange, rituximab, and intravenous immunoglobulin for acute exacerbations of idiopathic pulmonary fibrosis

Table 1 Outline of experimental arm interventions

Days on Intervention	1	2	3	4	5	6	7	8	9	11	13	15	16
Prednisone or equivalent (p.o. dose per day)	60 mg	20 mg each day				none	20 mg each day					none	20 mg each day
Therapeutic Plasma Exchange (TPE)	TPE, each of these days				TPE, each of these days				TPE	TPE	TPE	TPE
Rituximab						1 gm IV						1gm IV
Acetaminophen (prior to Rituximab)						650 mg Oral						650 mg Oral
Solumedrol (prior to Rituximab)						100 mg IV						100 mg IV
Benadryl -diphenhydramine (prior to Rituximab)						50 mg Oral						50 mg Oral
Antibiotics	x	x	x	x	x	x	x	x
IVIG													0.5 gm/kg/day

The experimental interventions (days 1-19) are outlined here
Maintenance steroid doses after Day 19 are at discretion of attending physician(s). Adverse events are prospectively recorded at these time points too, and at any time they may arise

ISSN: 1471-2466